Index After Acute Myocardial Infarction Research Articles

Predictors for early cardiac death after discharge from successfully treated acute myocardial infarction.

The use of a cardioverter defibrillator for the primary prevention of sudden cardiac death is not recommended within 40 days after acute myocardial infarction (AMI). We investigated the predictors for early cardiac death among patients who were admitted for AMI and successfully discharged. Consecutive patients with AMI were enrolled in a multicenter prospective registry. Among 10,719 patients with AMI, 554 patients with in-hospital death and 62 patients with early non-cardiac death were excluded. Early cardiac death was defined as a cardiac death within 90 days after index AMI. Early cardiac death after discharge occurred in 168/10,103 (1.7%) patients. A defibrillator was not implanted in all patients with early cardiac death. Killip class ≥3, chronic kidney disease stage ≥4, severe anemia, cardiopulmonary support usage, no dual antiplatelet therapy at discharge, and left ventricular ejection fraction (LVEF) ≤35% were independent predictors for early cardiac death. The incidence of early cardiac death according to the number of factors added to LVEF criteria in each patient was 3.03% for 0 factor, 8.11% for 1 factor, and 9.16% for ≥2 factors. Each model that sequentially added the factors in the presence of LVEF criteria showed a significant gradual increase in predictive accuracy and an improvement in reclassification capability. A model with all factors showed C-index 0.742 [95% CI 0.702-0.781], p < 0.001; IDI 0.024 [95% CI 0.015-0.033], p < 0.001; and NRI 0.644 [95% CI 0.492-0.795], p < 0.001. We identified six predictors for early cardiac death after discharge from AMI. These predictors would help to discriminate high-risk patients over current LVEF criteria and to provide an individualized therapeutic approach in the subacute stage of AMI.

Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.

Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI. In a prespecified substudy, 544 PARADISE-MI participants were enrolled in the Echo Study to undergo protocol echocardiography at randomization and after 8 months. Patients were randomized within 0.5 to 7 days of presentation with their index AMI to receive a target dose of sacubitril/valsartan 200 mg or ramipril 5 mg twice daily. Echocardiographic measures were performed at a core laboratory by investigators blinded to treatment assignment. The effect of treatment on change in echo measures was assessed with ANCOVA with adjustment for baseline value and enrollment region. The primary end points were change in LV ejection fraction (LVEF) and left atrial volume (LAV), and prespecified secondary end points included changes in LV end-diastolic and end-systolic volumes. Mean age was 64±12 years; 26% were women; mean LVEF was 42±12%; and LAV was 49±17 mL. Of 544 enrolled patients, 457 (84%) had a follow-up echo at 8 months (228 taking sacubitril/valsartan, 229 taking ramipril). There was no significant difference in change in LVEF (P=0.79) or LAV (P =0.62) by treatment group. Patients randomized to sacubitril/valsartan demonstrated less increase in LV end-diastolic volume (P=0.025) and greater decline in LV mass index (P=0.037), increase in tissue Doppler e'lat (P=0.005), decrease in E/e'lat (P=0.045), and decrease in tricuspid regurgitation peak velocity (P=0.024) than patients randomized to ramipril. These differences remained significant after adjustment for differences in baseline characteristics. Baseline LVEF, LV end-diastolic volume, LV end-systolic volume, LV mass index, LAV, and Doppler-based diastolic indices were associated with risk of cardiovascular death or incident heart failure. Treatment with sacubitril/valsartan compared with ramipril after AMI did not result in changes in LVEF or LAV at 8 months. Patients randomized to sacubitril/valsartan had less LV enlargement and greater improvement in filling pressure. Measures of LV size, systolic function, and diastolic properties were predictive of cardiovascular death and incident heart failure after AMI in this contemporary, well-treated cohort. URL: https://www. gov; Unique identifier: NCT02924727.

A UK retrospective analysis of recurrent cardiovascular events following acute myocardial infarction in patients with multivessel disease and additional risk factors

Abstract Background Patients with multivessel disease (MVD) are at increased risk of recurrent cardiovascular (CV) events in the early period after acute myocardial infarction (AMI) compared to patients without MVD, possibly due to increased atherosclerotic burden. Moreover, many have additional risk factors such as older age, peripheral artery disease (PAD), prior AMI or diabetes that could further increase risk of recurrent events. Real-world evidence regarding the impact of additional CV risk factors on outcomes in patients with MVD remains sparse. Purpose To assess clinical outcomes in the early period after AMI in a UK cohort of patients with MVD and additional risk factors. Methods A retrospective analysis (January 1, 2008–December 31, 2018, inclusive) was conducted using the Clinical Practice Research Datalink database linked to Hospital Episode Statistics and Office of National Statistics databases to identify patients with a confirmed diagnosis of MVD within the study period and at least one non-fatal myocardial infarction (MI) diagnosis code on or after their first recorded MVD diagnosis. The effect of diabetes on clinical outcomes was assessed by comparing patients diagnosed with diabetes on or prior to their index AMI with those with no concurrent diabetes diagnosis (MVD+DM and MVD-DM cohorts, respectively). Clinical outcomes were also assessed in AMI patients without diabetes but with at least two additional risk factors including: age &amp;gt;65 years, PAD diagnosis or prior MI diagnosis (MVD2RF+ cohort), and those with a single or none of the aforementioned risk factors (MVD2RF- cohort). Major adverse CV events (MACE) was defined as a composite of non-fatal AMI, non-fatal stroke or CV death. Results Of the 78,128 patients with MVD identified, 19,768 and 52,197 were eligible for inclusion in the MVD+DM and MVD-DM cohorts respectively. Occurrence of MACE was similar between the MVD+DM and MVD-DM cohorts at both 90 days (15% vs. 14%) and 1 year (19% vs. 17%) post-AMI; however, all-cause and CV mortality were significantly higher in the MVD+DM cohort over the study period (p&amp;lt;0.001). In the subset of patients without diabetes, 7,531 and 44,666 patients met the criteria for the MVD2RF+ and MVD2RF- cohorts, respectively. A substantially higher proportion of patients in the MVD2RF+ cohort experienced a MACE within 90 days or 1 year post-MI compared with the MVD2RF- cohort (90 days: 45% vs. 9%; 1 year: 56% vs. 11%), with non-fatal MI accounting for the majority of recurrent events. Kaplan-Meier survival analysis revealed that both all-cause and CV mortality were significantly higher in the MVD2RF+ than the MVD2RF- cohort (p&amp;lt;0.001). Conclusions Having multiple risk factors including older age, PAD and a history of AMI substantially increases the risk of recurrent events in patients with MVD, particularly in the early period after AMI. Strategies to reduce the systemic atherosclerotic burden and risk of recurrent events in these patients are needed. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): CSL Behring

Screen-detected atrial fibrillation (AF) and “micro-AF” after myocardial infarction in patients 70–82 years and risk of cardiovascular events in the OMEMI trial

Abstract Background Incident atrial fibrillation (AF) occurs in 5–10% of patients after acute myocardial infarction (AMI) and is associated with adverse outcomes. Guidelines now recommend screening for AF in all elderly patients. However, the yield of extended AF screening after AMI has not been investigated. Short episodes of consecutive irregular supraventricular ectopic beats, entitled “micro-AF”, are associated with the development of AF, but the prognostic importance of such findings after an AMI is unknown. Purpose To investigate the added value of two-week intermittent ECG screening to detect incident AF and “micro-AF” in elderly patients 12 months after an AMI, and its relation to risk of cardiovascular endpoints. Methods The OMega-3 fatty acids in Elderly patients with Myocardial Infarction (OMEMI) study investigated the effect of Omega-3 fatty acid supplementation on 2-year risk of major cardiovascular events (MACE; non-fatal AMI, stroke, revascularization, or hospitalization for heart failure) in 70–82 years old patients with a recent AMI. All patients had a 12-lead ECG performed at 3, 12 and 24 months. In addition, patients without known AF one year after the index AMI underwent a 2-week period of intermittent 30-second “thumb ECG” screening. Incident AF and “micro-AF” (episodes of ≥3 consecutive irregular supraventricular ectopic beats) were registered and adjudicated by at least two investigators who were blinded to outcome, and the association with risk of MACE was analyzed with logistic regression. Results Among 1014 patients in the OMEMI trial, 255 (25.1%) had known AF or AF identified at baseline. New-onset AF was detected clinically or at study visits in 39 patients. Screening by 2-week “thumb ECG” was performed in 567 participants without known AF, and identified unknown AF in 4 (0.7%) patients. Another 27 (4.8%) patients had “micro-AF” in at least one ECG recording. In 43 patients with incident AF, 21 (48.8%) experienced a MACE, compared to 114 out of 716 without any AF (15.9%; p&amp;lt;0.001), driven by a higher risk of new AMI or revascularization. Nine (33.3%) patients with “micro-AF” and 63 (12.2%) without “micro-AF” experienced a MACE (p=0.002), explained mostly by a higher risk of hospitalization for heart failure (p&amp;lt;0.001). Using patients without AF and “micro-AF” as reference, “micro-AF” was associated with an intermediate risk of MACE (OR 2.8: 95% CI 1.2–6.4) and new-onset AF with a high risk of MACE (OR 5.3; 95% CI 2.8–10.0). Conclusion Two-week intermittent ECG screening identified few new cases of new-onset AF, but a substantial number of patients with “micro-AF”. “Micro-AF” was associated with an increased risk of major cardiovascular events, albeit with an intermediate risk compared to a higher risk of major cardiovascular events associated with new-onset AF. Funding Acknowledgement Type of funding sources: None.

Trends in 10-Year Outcomes Among Medicare Beneficiaries Who Survived an Acute Myocardial Infarction

Short-term outcomes after acute myocardial infarction (AMI) have improved, but little is known about longer-term outcomes. To evaluate trends in 10-year all-cause mortality and hospitalization for recurrent AMI by demographic subgroups and examine the association between recurrence and mortality. Medicare fee-for-service beneficiaries who survived after AMI from 1995 to 2019. Subgroups were defined by age, sex, race, dual Medicare-Medicaid-eligible status, and residence in health priority areas (geographic areas with persistently high adjusted mortality and hospitalization rates). Data were analyzed from October 2020 to February 2022. Medicare fee-for-service beneficiaries who survived an AMI. Ten-year all-cause mortality and hospitalization for recurrent AMI, beginning 30 days from the index AMI admission. Of an included 3 982 266 AMI survivors, 1 952 450 (49.0%) were female, and the mean (SD) age was 78.0 (7.4) years. Ten-year mortality and recurrent AMI rates were 72.7% (95% CI, 72.6-72.7) and 27.1% (95% CI, 27.0-27.2), respectively. Adjusted annual reductions were 1.5% (95% CI, 1.4-1.5) for mortality and 2.7% (95% CI, 2.6-2.7) for recurrence. In subgroup analyses balancing patient characteristics, hazard ratios (HRs) for mortality and recurrence were 1.13 (95% CI, 1.12-1.13) and 1.07 (95% CI, 1.06-1.07), respectively, for men vs women; 1.05 (95% CI, 1.05-1.06) and 1.08 (95% CI, 1.07-1.09) for Black vs White patients; 0.96 (95% CI, 0.95-0.96) and 1.00 (95% CI, 1.00-1.01) for other race (including American Indian and Alaska Native, Asian, Hispanic, other race or ethnicity, and unreported) vs White patients; 1.24 (95% CI, 1.24-1.24) and 1.21 (95% CI, 1.20-1.21) for dual Medicare-Medicaid-eligible vs non-dual Medicare-Medicaid-eligible patients; and 1.06 (95% CI, 1.06-1.07) and 1.00 (95% CI, 1.00-1.01) for patients in health priority areas vs other areas. For patients hospitalized in 2007 to 2009, the last 3 years for which full 10-year follow-up data were available, 10-year mortality risk was 13.9% lower than for those hospitalized in 1995 to 1997 (adjusted HR, 0.86; 95% CI, 0.85-0.87) and 10-year recurrence risk was 22.5% lower (adjusted HR, 0.77; 95% CI, 0.76-0.78). Mortality within 10 years after the initial AMI was higher for patients with a recurrent AMI (80.6%; 95% CI, 80.5-80.7) vs those without recurrence (72.4%; 95% CI, 72.3-72.5). In this study, 10-year mortality and hospitalization for recurrence rates improved over the last decades for patients who survived the acute period of AMI. There were marked differences in outcomes and temporal trends across demographic subgroups, emphasizing the urgent need for prioritization of efforts to reduce inequities in long-term outcomes.

Hospital readmissions and economic burden associated with multivessel disease in the early period following acute myocardial infarction

Abstract Background There is emerging evidence that particularly high rates of major adverse cardiovascular events (MACE) occur in the 90-day period after acute myocardial infarction (AMI). Post-AMI MACE are associated with additional resource utilization and economic burden for healthcare systems, with multivessel disease (MVD) conferring a 3- to 4-fold increase in risk of recurrent MACE in the first year post AMI vs. single vessel disease. Thus, characterizing the prevalence and outcomes of patients with MVD and various comorbidities is crucial to predict and mitigate clinical risk and associated costs. Purpose To describe post-AMI readmissions and economic burden in MVD patients at 30, 90, and 365 days. Methods This was a retrospective cohort study (1st January, 2008 to 31st December, 2018). Patients with MVD were identified by a confirmed diagnosis code from a longitudinal, representative UK population health dataset comprising primary care data from the Clinical Practice Research Datalink (CPRD), which was linked to secondary care data from the Hospital Episode Statistics (HES) and Office of National Statistics (ONS) databases. Patients who experienced at least one AMI after their first recorded MVD diagnosis were defined as MVD+. A MACE was defined as any one of non-fatal MI, non-fatal stroke, or cardiovascular death. Readmissions were defined as non-elective admissions with a MACE outcome diagnosis occurring up to 28 days from a previous admission with the same treatment speciality. Results The study population included 78,128 MVD+ patients (4.2% of the total patient population). In the MVD+ cohort, 3,753 (4.8%) patients were readmitted with at least one MACE event or other non-elective admission within the cardiovascular specialty: 2,394 (63.8%), 2,562 (68.3%), and 2,830 (75.4%) readmissions occurred within 30, 90, and 365 days, respectively. The mean length of hospital stay per patient, per readmission for MACE within 30, 90, and 365 days was 7.22, 7.46, and 7.74 days, respectively. The mean cost per MACE admission within 90 days of index AMI was £3,926.52. Non-fatal MI was the most common reason for readmission at all timepoints. Percutaneous transluminal balloon angioplasty and saphenous vein graft procedures (coronary artery bypass graft, CABG) were among the most common cardiac procedures in MVD+ patients, at 70,276 (22.7%) and 15,418 (5.0%), respectively. Conclusions In patients with MVD who suffer an AMI, there is high resource utilization and cost, particularly in the first 90-days post AMI; therefore, the 90-day post-AMI period represents significant economic costs to healthcare systems. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): CSL Behring

Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study

BackgroundData are scarce regarding the risk, temporal trends and predictors of late-onset heart failure (LOHF) after acute myocardial infarction (AMI). We aimed at studying the risk and predictors of LOHF and the composite event of LOHF or death after AMI. MethodsAMI patients first entered in the nationwide SWEDEHEART registry between 2004 and 2013 were included. Patients with a prior history of heart failure (HF) and those who died in-hospital were excluded. Dates and ICD-codes for LOHF in the national patient and death registries were used to determine time to first readmission due to LOHF and/or death. ResultsA total of 150,566 AMI patients were included in the analysis. The 1-year, 2-year and 5-year cumulative risk of developing LOHF were 11.4%, 14.6% and 21.8% respectively. The risk of LOHF within 2years decreased from 15.5% to 14.4% (2004–2005 vs 2010–2011), p<0.001. Calendar year was protective of LOHF/death after adjustment (HR 0.96, 95% CI 0.94–0.98, p<0.001). In-hospital HF, age, diabetes mellitus, chronic kidney disease, peripheral arterial disease, chronic obstructive pulmonary disease and atrial fibrillation, were strong predictors of LOHF. Risk profile improved and use of evidence based therapies increased during the time period. ConclusionsSurvivors of AMI remain at a continued risk of LOHF. However, the overall risk of LOHF shows a decreasing trend after an index AMI over time. Lower risk of LOHF may relate to decreasing burden of comorbidities and increasing use of evidence based treatments.

Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.

BackgroundA number of registry studies have reported suboptimal adherence to guidelines for cardiovascular prevention during the first year after acute myocardial infarction (AMI). However, only a few studies have addressed long-term secondary prevention after AMI. This study evaluates prevention guideline adherence and outcome of guideline-directed secondary prevention in patients surviving 2 years after AMI.MethodsPatients aged 18–85 years at the time of their index AMI were consecutively identified from hospital discharge records between July 2010 and December 2011 in Gothenburg, Sweden. All patients who agreed to participate in the study (16.2%) were invited for a structured interview, physical examinations and laboratory analysis 2 years after AMI. Guideline-directed secondary preventive goals were defined as optimally controlled blood pressure, serum cholesterol, glucose, regular physical activity, smoking cessation and pharmacological treatment.ResultsThe mean age of the study cohort (n = 200) at the index AMI was 63.0 ± 9.7 years, 79% were men. Only 3.5% of the cohort achieved all six guideline-directed secondary preventive goals 2 years after infarction. LDL < 1.8 mmol/L was achieved in 18.5% of the cohort, regular exercise in 45.5% and systolic blood pressure <140 mmHg in 57.0%. Anti-platelet therapy was used by 97% of the patients, beta-blockers by 83.0%, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers by 76.5% and statins by 88.5%. During follow-up, non-fatal adverse cardiovascular events (cardiac hospitalization, recurrent acute coronary syndrome, angina pectoris, new percutaneous coronary intervention, new onset of atrial fibrillation, post-infarct heart failure, pacemaker implantation, stroke/transient ischemic attack (TIA), cardiac surgery and cardiac arrest) occurred in 47% of the cohort and readmission due to cardiac causes in 30%.ConclusionsOur data showed the failure of secondary prevention in our daily clinical practice and high rate of non-fatal adverse cardiovascular events 2 years after AMI.

Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009

Few contemporary studies examine trends in recurrent coronary heart disease (CHD) events and mortality after acute myocardial infarction (AMI) and whether these trends vary by race or sex. We used data from the national 5% random sample of Medicare fee-for-service beneficiaries for 1999 to 2010. We included beneficiaries who experienced an AMI (International Classification of Disease [ICD] 9 410.xx, except 410.x2) between January 1, 2001, and December 31, 2009. Each beneficiary's first AMI was included as their index event. Outcomes included all-cause mortality, recurrent AMI, and recurrent CHD events during the 365days after discharge for the index AMI. To examine secular trends, we pooled calendar years into 3 periods (2001-2003, 2004-2006, and 2007-2009). Among 48,688 beneficiaries with index AMIs from 2001 to 2009, we observed decreases in the age-adjusted rates for mortality (-3.8% for each 3-year period, 95% CI -6.1% to -1.6%, P trend = .001), recurrent AMI (-15.0%, 95% CI -18.6% to -11.2%, P trend < .001), and recurrent CHD events (-11.1%, 95% CI -14.0% to -8.0%, P trend < .001) in the 365days after the index AMI. In 2007 to 2009, blacks had excess risk relative to whites for mortality and recurrent AMI (black/white incidence rate ratio of 1.38 for mortality [95% CI 1.21-1.57] and 1.38 for recurrent AMI [95% CI 1.07-1.79]). Despite overall favorable trends in lower mortality and recurrent events after AMI, efforts are needed to reduce racial disparities.

Impaired Diastolic Recovery after Acute Myocardial Infarction as a Predictor of Adverse Events.

BackgroundTo investigate the impact of left ventricular (LV) diastolic functional recovery on major adverse cardiac events (MACE) 6 months after acute myocardial infarction (AMI) in patients with preserved LV systolic function.MethodsA total 463 patients with preserved LV systolic function at 6 months after an AMI were divided into two groups based on the extent of diastolic recovery assessed by echocardiography: group I (n = 241) showed improving diastolic function and group II (n = 222) did not. MACE included death, recurrent myocardial infarction, and rehospitalization due to heart failure, and these events were compared with the patients' characteristics at baseline.ResultsCompared with group I, the patients in group II were older and had a higher prevalence of hypertension and diabetes. Blood levels of hemoglobin and triglyceride were lower in group II, whereas the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and of high-sensitivity C-reactive protein were higher in this group than in group I. MACE were significantly more frequent in group II than in group I. Age, elevated NT-proBNP, and impaired diastolic recovery were significant independent predictors of MACE.ConclusionDespite improvement in LV systolic function, LV diastolic function had not improved in 222 patients (47.9%) by the 6-month follow-up after the index AMI, and impaired diastolic functional recovery was found to be an independent predictor of MACE. Evaluation of diastolic function would be a useful way to stratify risk in patients discharged after an index AMI.

Abstract 104: The Effect of Low Perceived Social Support on Health Outcomes in Young Patients with Acute Myocardial Infarction: Results from the VIRGO Study

Background: Social support is an important predictor of health outcomes after acute myocardial infarction (AMI), but significant variability in social support exists by sex and age. Most studies have been conducted in populations of predominately older, male patients; little is known about the impact of social support on outcomes after AMI in young patients, who may have unique demands and resources. Methods: We used data from the VIRGO study, an observational study of patients aged ≤55 years with AMI in the US and Spain, to examine the association of low perceived social support (LPSS) with baseline and 1-year health status, depression, and quality of life. Patients were categorized as having low vs. moderate/high social support using the ENRICHD Social Support Inventory (ESSI), which was collected during the index AMI hospitalization. A modified 5-item version of the 7-item ESSI was used for this study in order to examine marital status and instrumental support separately from perceived social support. Outcomes included health status (assessed by the Short Form-12 (SF-12) physical and mental component scores (PCS and MCS)), depressive symptoms (Patient Health Questionnaire (PHQ-9)), and angina-related quality of life (Seattle Angina Questionnaire (SAQ)) evaluated at baseline and 1-year. We used linear regression to compare 1-year health status between social support categories, adjusting for baseline health status, socio-demographics, comorbidities, severity of disease, and therapies used. Results: Among 3,432 patients, 728 (21.2%) were classified as having LPSS. Men and women had comparable levels of social support at baseline. On average, patients with LPSS reported lower functional status (PCS and MCS), lower quality of life, and more depressive symptoms at baseline and 1-year post-AMI. After multivariable adjustment, including baseline health status, LPSS was associated with lower mental functioning (mean MCS -2.34 (95% confidence interval [CI] -3.35, -1.34) p&lt;0.001), lower quality of life (mean SAQ -4.58 (95% CI -4.58, -2.57), p&lt;0.001), and more depressive symptoms (1.01 (95% CI 0.52, 1.51), p&lt;0.001) at 1 year. The relationship between LPSS and worse physical functioning was not significant after adjustment (mean PCS -0.28 (95% CI -1.33, 0.77), p=0.6). We observed no interactions between social support, sex or country. Conclusion: Lower social support is associated with worse health status and more depressive symptoms 1-year after AMI in both young men and women recovering from an AMI.

Prevalent But Moderate Variation Across Small Geographic Regions in Patient Nonadherence to Evidence-based Preventive Therapies in Older Adults After Acute Myocardial Infarction

Patient long-term adherence to β-blockers, HMG-CoA reductase inhibitors (statins), and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) after acute myocardial infarction (AMI) is alarmingly low. It is unclear how prevalent patient adherence may be across small geographic areas and whether this geographic prevalence may vary. This is a retrospective cohort study using Medicare service claims files from 2007 to 2009 with Medicare beneficiaries 65 years and above who were alive 30 days after the index AMI hospitalization between January 1, 2008 and December 31, 2008 (N=85,017). The adjusted proportions of patients adherent to β-blockers, statins, and ACEIs/ARBs, respectively, in the 12 months after discharge across the 306 Hospital Referral Regions (HRRs) were measured and compared by control chart. The intracluster correlation coefficient (ICC) and the additional prediction power from this small-area variation on individual patient adherence were assessed. The adjusted proportion of patients adherent across HRRs ranged from 58% to 74% (median, 66%) for β-blockers, from 57% to 67% (median, 63%) for ACEIs/ARBs, and from 58% to 73% (median, 66%) for statins. The ICC was 0.053 (95% CI, 0.043-0.064) for β-blockers, 0.050 (95% CI, 0.039-0.061) for ACEIs/ARBs, and 0.041 (95% CI, 0.031-0.052) for statins. The adjusted proportion of patients adherent across HRRs increased the c-statistic by 0.01-0.02 (P < 0.0001). Nonadherence to evidence-based preventive therapies post-AMI among older adults was prevalent across small geographic regions. Moderate small-area variation in patient adherence exists.

Stroke : Highlights of Selected Articles

<i>Stroke</i> : Highlights of Selected Articles

Culprit versus non-culprit lesion related adverse cardiac events in patients with obstructive sleep apnoea

BackgroundIn patients with obstructive sleep apnoea (OSA), the relative contribution of culprit versus non-culprit lesions to subsequent major adverse cardiac events (MACE) after acute myocardial infarction (AMI) remains unknown. Elucidating...

Diagnostic Procedures, Revascularization, and Inpatient Mortality After Acute Myocardial Infarction in Patients With Schizophrenia and Bipolar Disorder

To investigate inpatient mortality and the use of invasive diagnostic and revascularization procedures after acute myocardial infarction (AMI) in people with schizophrenia and bipolar disorder. A case-control study was nested within the first AMI episodes between 1996 and 2007 using nationwide data. Participants with schizophrenia or bipolar disorder were compared with a random sample of all other adults without severe mental illness. Inpatient mortality and receipt of cardiac catheterization, coronary arteriography, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft were compared in logistic regression models after adjusting for demographic and health status, hospital type, and AMI complications. A total of 3361 adult patients who had incident AMI between 1996 and 2007 were identified. Patients with schizophrenia and bipolar disorder (n = 834; 24.8%) had a significantly decreased likelihood of catheterization (12.2% and 14.0%, respectively) and revascularization (9.0% and 12.8%, respectively) during the index AMI episode compared with controls (27.9% of whom received catheterization and 23.9% of whom received revascularizations). Inpatient mortality remained 2.68 times the rate in patients with schizophrenia (95% confidence interval = 1.73-4.15; p < .001) compared with controls after adjusting for intervention receipt among other covariates, but mortality was not significantly raised in patients with bipolar disorder. In a large national sample and in the context of a comprehensive free health service, patients with schizophrenia and bipolar disorder were substantially disadvantaged, being half as likely to receive catheterization or revascularization procedures after AMI. Further research is required to clarify the reasons for this.

Abstract 116: Is There Gender Disparity in the Use of Drug Eluting Stents after Acute Myocardial Infarction?

Background: Women are less likely than men to have cardiac catheterization and percutaneous coronary intervention (PCI) after acute myocardial infarction (AMI). It is unclear whether such gender disparity extends to the implantation of the type of coronary stent (bare metal stent (BMS) versus drug eluting stent (DES)) after AMI. Methods: We examined coronary stent implantation by type within 30 days of AMI in 33,748 patients admitted to non-federal hospitals in New Jersey using a statewide database. Data from 2003 through 2009 in the Myocardial Infarction Data Acquisition System (MIDAS) were used to identify patients with first episode of AMI and single type (BMS versus DES) of coronary stent implantation after the AMI. Multivariate logistic regression was used to analyze the differences by gender after adjustment for age, race, insurance, site of MI, pre-or post discharge stent implantation, and co-morbidities. Results: Coronary stent implantations after AMI were stratified by placement periods into: at index of AMI admission, n=16,719; within 2 days, n=22,019; within one week, n=31,618; and within 30 days of index AMI, n=33,748. In 2003, the use of BMS in women declined from 76% (386 of 507) to 68% (986 of 1454) from index AMI to 30 days, and in men from 79% (930 of 1181) to 70% (2017 of 2863). The use of DES in women increased from 24% (121 of 507) at index AMI to 32% (468 of 1454) at 30 days, and in men from 21% (251 of 1181) to 30% (846 of 2863). After adjustment for covariates, in 2003, women were more likely to receive DES than men within 2 days of the index AMI [Odds Ratio (OR): 1.37; 95% Confidence Interval (CI): (1.10, 1.70); p = 0.005], within 1 week of index AMI [OR: 1.21; CI (1.03,1.41); p= 0.02], within 30 days of index AMI [OR: 1.20; CI (1.03, 1.39); p = 0.02)]. In 2004 through 2009, both men and women had higher proportion of DES than BMS implantation after AMI. However, there was no significant gender difference in stent type for these years, except in 2006 when DES implants (received within 1 week and 30 days of index AMI) were significantly more frequent in women compared to men. Conclusion: Although women are less likely to receive PCI compared to men after AMI, there is generally no gender difference in the proportion of DES versus BMS received in contemporary years.

Comparison of Effects of Primary Coronary Angioplasty on Left Ventricular Remodeling and Heart Failure in Patients

Experimental studies have demonstrated the adverse effects of senescence on cardiac function and remodeling after acute myocardial infarction (AMI). We sought to assess the impact of age on left ventricular (LV) remodeling and heart failure (HF) after successful primary angioplasty for AMI. A series of 512 consecutive patients underwent 2-dimensional echocardiography at admission and at 1 month and 6 months after index AMI. LV volumes, ejection fraction, and wall motion score index (WMSI) were measured. Patients were divided in group 1 (<70 years old, n = 361) and group 2 (> or =70 years old, n = 151). Group 2 patients showed a lower peak creatine kinase (p = 0.029) compared to group 1. In group 2 patients the 6-month prevalence of LV remodeling (increase >20% in end-diastolic volume) was higher (34% vs 25%, p = 0.041), recoveries of ejection fraction and WMSI were lower (p = 0.00002 for the 2 comparisons), and incidence of late HF was higher (35% vs 17%, p <0.0001) compared to group 1 patients. Independent predictors of LV remodeling were WMSI (p <0.0001), infarct size (p <0.0001), and LV end-diastolic volume (p <0.0001). Independent predictors of late HF were WMSI (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.624 to 4.514), 6-month LV dilation (HR 2.13, 95% CI 1.404 to 3.233), diabetes (HR 1.6, 95% CI 1.008 to 2.595), infarct size (HR 1.12, 95% CI 1.037 to 1.215), and age as continuous variables (HR 1.064, 95% CI 1.044 to 1.085). In conclusion, besides infarct size, extensive regional systolic dysfunction may play a significant role in the development of LV remodeling and HF in patients > or =70 years old after successful primary angioplasty.

Influence of Socioeconomic Status on Lifestyle Behavior Modifications Among Survivors of Acute Myocardial Infarction

The impact of secondary prevention initiatives on survival in higher-risk socioeconomically disadvantaged patients after acute myocardial infarction (AMI) may depend on behavioral adaptive responsiveness, uptake, and adherence to healthier lifestyles. From December 1999 to February 2003, 1,801 patients in Ontario, Canada were interviewed regarding their lifestyle behaviors at 30 days after their index AMI hospitalization. Data were obtained using self-reported surveys, medical chart abstraction, and administrative data linkage. Multivariate analyses were adjusted for baseline sociodemographic, cardiac risk severity, and co-morbid conditions. Socioeconomically disadvantaged patients had greater cardiac risk severity at baseline than did their wealthier better-educated counterparts. Compared with lower-income patients, patients with higher incomes were less likely to smoke (adjusted odds ratio [OR] for highest vs lowest income tertiles 0.36, 95% confidence interval [CI] 0.21 to 0.63, p <0.001), more likely to participate in exercise (adjusted OR 1.40, 95% CI 1.07 to 1.85, p = 0.02), and more likely to decrease or discontinue alcohol use (adjusted OR 1.64, 95% CI 1.16 to 2.34, p = 0.06). The relation between education and lifestyle behaviors was less pronounced for education than for income. After adjustment for baseline factors, patients who acknowledged participation in regular physical exercise at 1 month had a significantly lower long-term mortality than those who did not. In conclusion, socioeconomically disadvantaged patients were sicker at baseline and less behaviorally responsive to embarking on healthy lifestyle changes after AMI than were those of higher socioeconomic status.

Comparison of Usefulness of Left Ventricular Diastolic Versus Systolic Function as a Predictor of Outcome Following Primary Percutaneous Coronary Angioplasty for Acute Myocardial Infarction

Left ventricular (LV) diastolic function is an important predictor of morbidity and mortality after acute myocardial infarction (AMI). We evaluated the role of diastolic function in predicting in-hospital events and LV ejection fraction (EF) 6 months after a first AMI that was treated with primary percutaneous coronary intervention (PCI). We prospectively enrolled 59 consecutive patients who were 60 +/- 15 years of age (48 men), presented at our institution with their first AMI, and were treated with primary PCI. Patients underwent 2-dimensional and Doppler echocardiography, including tissue Doppler imaging of 6 basal mitral annular regions within 24 hours after primary PCI and were followed until discharge. Clinical and echocardiographic variables at index AMI were compared with a combined end point of cardiac death, ventricular tachycardia, congestive heart failure, or emergency in-hospital surgical revascularization. Follow-up echocardiographic assessment was performed at 6 months in 24 patients. During hospitalization, 3 patients died, 7 developed congestive heart failure, 4 had ventricular tachycardia, and 1 required emergency surgical revascularization. Stepwise logistic regression analysis showed the ratio of early mitral inflow diastolic filling wave (E) to peak early diastolic velocity of non-infarct-related mitral annulus (p < 0.01) (E') and mitral inflow E-wave deceleration time (p < 0.02) to be independent predictors of in-hospital cardiac events (generalized R2 = 0.66). In a stepwise multiple linear regression model, independent predictors of follow-up LVEF were mitral inflow deceleration time (R2 = 0.39, p = 0.002), baseline LVEF (R2 = 0.54, p < 0.02), and mitral inflow peak early velocity/mitral annular peak early velocity (or E/E') of infarct annulus (R2 = 0.66, p = 0.02). In conclusion, in patients who are treated with primary PCI for a first AMI, E/E' velocity ratio and mitral inflow E-wave deceleration time are strong predictors of in-hospital cardiac events and of LVEF at 6-month follow-up.

Prognostic Value of Charlson Comorbidity Index at 30 Days and 1 Year After Acute Myocardial Infarction

The Charlson comorbidity index (CCI), an indicator of comorbidity, has been used as an adjusting variable in multivariate models. Because of its prognostic value per se for cardiovascular complications after acute myocardial infarction (AMI), we sought to determine the predictive value of the CCI for all-cause mortality and recurrent AMI 30 days and 1 year after the index event. We analyzed 1035 consecutive patients admitted with the diagnosis of AMI (ST elevation=508 and non-ST elevation=527). The composite endpoint was determined after 30 days (13.9%) and 1 year (26.3%) of follow-up. The CCI was calculated on admission, and other variables with prognostic value were also recorded. CCI was stratified in 4 categories: 1: CCI=0 (control), 2: CCI=1, 3: CCI=2,4: CCI> or =3. Cox proportional risks analysis was used for the multivariate analysis, and the C-statistic was calculated to assess the discriminative power of the models. Hazard ratios (95% CI) estimated for each category of CCI were: 2=1.69 (1.10-2.59), 3=1.78 (1.08-2.92) and 4=1.57 (0.87-2.83) at 30 days; 2=1.62 (1.18-2.23), 3=2.00 (1.39-2.89) and 4=2.24 (1.50-3.36) at 1 year. Comparisons with the C-statistic between the nested multivariate models (with and without CCI) yielded values of 0.765 vs 0.750 after 30 days, and 0.751 vs 0.735 after 1 year. Our data indicate that CCI is an independent predictor of mortality or recurrent AMI 30 days and 1 year after the index AMI.